Pragmatic Person-Centered Care for Diabetes in Myanmar: A Narrative Review and Expert Insights From an Advisory Board Meeting.
13 affiliations
- 1Endocrinology, Myanmar Diabetes Association, Yangon, MMR.
- 2Diabetes and Endocrinology, Grand Hantha International Hospital, University of Medicine 2, Yangon, Yangon, MMR.
- 3Endocrinology, University of Medicine 2, Yangon, Yangon, MMR.
- 4Endocrinology, Grand Hantha International Hospital, Yangon, MMR.
- 5Endocrinology, Bharti Hospital, Karnal, IND.
- 6Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital, Vellore, Vellore, IND.
- 7Medicine, University of Medicine 1, Yangon, Yangon, MMR.
- 8Medical Unit 1, Yangon General Hospital, Yangon, MMR.
- 9Diabetes and Endocrinology, Yangon General Hospital, University of Medicine, Mandalay, Mandalay, MMR.
- 10Diabetes and Endocrinology, University of Medicine, Mandalay, Mandalay, MMR.
- 11Endocrinology, University of Medicine, Magway, Magway, MMR.
- 12Endocrinology and Medicine, Thingangyun General Hospital, University of Medicine 2, Yangon, MMR.
- 13Diabetes and Endocrinology, North Oakkalapa General Hospital, University of Medicine 2, Yangon, MMR.
Abstract
Diabetes causes considerable morbidity and mortality in Myanmar. A pragmatic person-centered care (PCC) approach offers a holistic and individualized strategy. This expert opinion paper explores perspectives from Myanmar and Indian experts on diabetes burden, the role of PCC, and the barriers to its implementation. An advisory board meeting in December 2024 included expert-led sessions. Patient, physician, healthcare system, and curriculum-related challenges in implementing PCC were identified. However, Myanmar's cultural strengths deeply rooted in Buddhist philosophy may support PCC adoption. Personalized pharmacotherapy was emphasized. Metformin remained a preferred initial agent, while sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were favored for individuals with high cardio-renal risk, independent of metformin use.
Related
- The maturation of precision medicine into pragmatic, patient-centered care: A commentary on the 2026 EHA CLL Guidelines.
- Natural Products in Diabetes Mellitus: A Narrative Review of Mechanistic Insights into Metabolic Regulation and Therapeutic Potential
- Insights from the young people who serve on youth advisory councils in Africa: a mixed-methods study
- Developing and evaluating per-protocol adherence definitions in a large pragmatic clinical trial: insights from the Diuretic Comparison Project
- Patient-Centered Transition to Clean Intermittent Catheterization After a Sacrectomy for Sacral Chordoma: A Case Report and Narrative Review
BibTeX
@article{latt2026pragmatic,
title = {{Pragmatic Person-Centered Care for Diabetes in Myanmar: A Narrative Review and Expert Insights From an Advisory Board Meeting.}},
author = {Tint Swe Latt and Than T Aye and Ko Ko and Khin Saw Than and Sanjay Kalra and Nitin Kapoor and Thein Myint and San S Win and Htet Htet Khin and Ni Ni Hlaing and Kyaw Thu Yaa and Maung Maung Thant and Kyar Nyo S Myint and Yar Pyae},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116808},
url = {https://europepmc.org/article/MED/42926879},
note = {CC BY},
}
RIS
TY - JOUR
TI - Pragmatic Person-Centered Care for Diabetes in Myanmar: A Narrative Review and Expert Insights From an Advisory Board Meeting.
AU - Tint Swe Latt
AU - Than T Aye
AU - Ko Ko
AU - Khin Saw Than
AU - Sanjay Kalra
AU - Nitin Kapoor
AU - Thein Myint
AU - San S Win
AU - Htet Htet Khin
AU - Ni Ni Hlaing
AU - Kyaw Thu Yaa
AU - Maung Maung Thant
AU - Kyar Nyo S Myint
AU - Yar Pyae
PY - 2026
DA - 2026/09/23
JO - Cureus
DO - 10.7759/cureus.116808
UR - https://europepmc.org/article/MED/42926879
AB - Diabetes causes considerable morbidity and mortality in Myanmar. A pragmatic person-centered care (PCC) approach offers a holistic and individualized strategy. This expert opinion paper explores perspectives from Myanmar and Indian experts on diabetes burden, the role of PCC, and the barriers to its implementation. An advisory board meeting in December 2024 included expert-led sessions. Patient, physician, healthcare system, and curriculum-related challenges in implementing PCC were identified. However, Myanmar's cultural strengths deeply rooted in Buddhist philosophy may support PCC adoption. Personalized pharmacotherapy was emphasized. Metformin remained a preferred initial agent, while sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were favored for individuals with high cardio-renal risk, independent of metformin use.
SN - 2168-8184
ER -